certify
Home arrow Article arrow Article Detail

Mayo Clinic Researchers Partner with Triall to Advance Blockchain Technology in Clinical Trial Data

Profile Image

Indrani bose Follow

INDIA

Sep, 02 2022

Sep, 02 2022

likes | comments 0

Article Image

Researchers at the American nonprofit medical center Mayo Clinic have teamed up with Triall, a supplier of a blockchain-integrated eClinical platform, to improve clinical trial design and management of study data. This partnership will lead the world will take a significant step closer to decentralized clinical research  


Starting in September of this year, a 2-year multi-center pulmonary arterial hypertension trial including 10 research sites and more than 500 patients will be supported by Triall's eClinical platform. The key trial activities, such as data collection, document management, study monitoring, and eConsent, will all be supported by Triall's eClinical technologies. 


In order to strengthen clinical data integrity "end-to-end," from research start-up through study close-out and post-study activities, the cooperation takes a novel tack by elaborating how Triall's Verifiable Proof API can be leveraged to establish immutable blockchain-registered audit trails. As more data are gathered from a wider range of systems and devices, ensuring data integrity is becoming a bigger concern for clinical trial stakeholders and a significant roadblock to efficient and trustworthy medical research in the digital age. 


Also Read | Formula One registers for two trademarks related to NFTs and cryptocurrency


The audit trail will give researchers, monitors, IRBs, regulators, and other trial stakeholders a system-independent interface for quickly assessing the existence and integrity of trial-related documents and data, as well as their chronological order in the study process. As a result, Mayo Clinic and Triall can collaborate in the future towards establishing a proof-based environment for decentralized clinical research, while reinforcing their positions as thought leaders in clinical trial innovation. If the project is a success, Triall intends to continue working with the Mayo Clinic on decentralized medical research. 


About Triall :

Triall was introduced in 2018. Verial eTMF is the company's first blockchain product. Its helps researchers to produce verifiable evidence of the clinical trial materials' authenticity, such as the patient diagnosis information. Additionally, through eClinical, the company is creating APIs that will allow connected third-party clinical trial software suppliers to use Triall's blockchain infrastructure. For ecosystem utility, such as compensating clinical trial participants, the native TRL coin is created. 


For all essential research operations, including EDC, ePRO/eCOA, eSource, eConsent, eTMF, CTMS, RTSM, Wearable integration, and others, Triall provides a modular and completely integrated suite of eClinical solutions. Additionally, Triall uses Self-Sovereign Identity (SSI) technology to provide patients and research professionals more ownership and control over their data, papers, and processes. Triall also uses blockchain to produce verifiable confirmation of the integrity of clinical trial data. 

 


likes | comments 0

Profile Image

Indrani bose

CBW - External Analyst

INDIA

Comments
Data Centre Construction - World First artificial intelligence AI-Tech Utility Token
banner
Article
WMG team up with OpenSea to expand Web3 opportunities 

WMG?team up?with OpenSea?to expand?Web3 opportunities for artists. This platform will enable artists to?build and extend their fanbase in the Web3 community. The nonfungible token (NFT) marketplace..;

Disclaimer: The information is for informational purposes only.​ This advertisement does not constitute financial advice or any other advice. You should consult with a financial professional to determine what may be best for your individual needs. None of the information and/or content available through this advertisement is intended as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any company, financial product, security or commodity. To the maximum extent permitted by law, we disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations prove to be inaccurate, incomplete or unreliable or result in any investment or other losses. In Making the investment decision, investors must rely on their own examination of the issuer and the terms of the offerings, including the merits and risks involved. Investments are speculative, illiquid, and involve a high degree of risk , including the possible loss of investment.